The chronic heart failure (CHF)
market is a mature market that has been slowly overtaken by generic drugs, and
more branded products are expected to lose market exclusivity during the next
few years. GlobalData predicts that the major global barriers that will play a
crucial role in narrowing the global growth of the CHF market over the forecast
period include the sparsely populated CHF pipeline and an increasing number of
generic competitors in a market that is already heavily laden with generic
drugs.
However, the market entry of entry
of Novartis’ LCZ-696, the first novel, branded CHF drug to enter the market in
five years, will noticeably enhance the overall market size during the forecast
period. LCZ-696 is currently being evaluated in a trial for patients with heart
failure with reduced ejection fraction (HF-REF), but if clinical trial data
continue to demonstrate the drug’s efficacy in patients with heart failure with
preserved ejection fraction (HF-PEF), and it gains approval for use in this
population, it will be the first drug to show efficacy in this largely
underserved patient population. In addition, increased use of MRAs over the
forecast period in all seven major markets (7MM) will contribute to the
increase in the global CHF market size.
To
Read The Complete Report with TOC : http://www.marketresearchreports.biz/analysis-details/pharmapoint-chronic-heart-failure-global-drug-forecast-and-market-analysis-to-2022
Scope
- Overview of CHF, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines.
- Annualized CHF therapeutics market revenue, annual cost
of therapy and treatment usage pattern data from 2011-2012 and forecast
for ten years to 2022.
- Key topics covered include strategic competitor
assessment, market characterization, unmet needs, clinical trial mapping
and implications for the CHF therapeutics market.
- Pipeline analysis: comprehensive data split across
different phases, emerging novel trends under development, including both
pharmacological and non-pharmacological therapeutic approaches.
- Analysis of the current and future market competition
in the global CHF therapeutics market. Insightful review of the key
industry drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Market Model Features
An interactive excel forecast model
based on primary research interviews and surveys with KOLs and high-prescribing
physicians is included in this report*. This patient based model provides
diagnosis rates, patient segmentation, treatment rates, annual costs of therapy
, and indication-specific drug sales for the 10 year forecast period. The
forecast model is robust, fully transparent, and easy to navigate. Moreover,
our models support data presented in the reports and the complete methodology
is outlined in the report and the model.
*Model only available with site and
global license purchases.
Key Findings
- An increasing number of generic competitors present a
significant barrier to growth in a market already heavily laden with
generic drugs.
- The launch of Novartis’s LCZ-696, a new market entrant,
will drive the overall growth of the CHF market in the 7MM during
2012-2022.
- To date, no drug has demonstrated sufficient efficacy
in the HF-PEF segment of the CHF population in large-scale clinical
trials. This unmet need presents a large opportunity for investment by
drug developers.
Key Questions Answered in this
Report
- Although the CHF market has numerous well-established
therapies, it is marked by the presence of a number of unmet needs in
current treatments. What are the main unmet needs in this market? Will the
drugs under development fulfil the unmet needs of the CHF market?
- The late-stage CHF developmental pipeline is sparsely
populated, however, the early stage pipeline is more active and consists
of novel pharmacological as well as non-pharmacological therapeutic
approaches. Will the late-stage drugs make a significant impact on the CHF
market? What are the earlier-stage novel, approaches that drug developers
are pursuing?
- Although the incidence of CHF in the US has been
relatively constant during the last decade, its prevalence has been
gradually increasing. How will epidemiological changes impact the growth
of the future market?
Key Benefits
- Develop and design your in-licensing and out-licensing
strategies through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally a
list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends
shaping and driving the global CHF therapeutics market.
- Drive revenues by understanding the key trends,
innovative products and technologies, market segments, and companies
likely to impact the global CHF therapeutics market in future.
- Formulate effective sales and marketing strategies by
understanding the competitive landscape and by analyzing the performance
of various competitors.
- Identify emerging players with potentially strong
product portfolios and create effective counter-strategies to gain a
competitive advantage.
- Track drug sales in the global CHF therapeutics market
from 2012-2022.
- Organize your sales and marketing efforts by
identifying the market categories and segments that present maximum
opportunities for consolidations, investments and strategic partnerships.
About
Us
MarketResearchReports.Biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are especially designed to save time and
money of our clients. We are a one stop solution for all your research needs, our
main offerings are syndicated research reports, custom research, subscription
access and consulting services. We serve all sizes and types of companies
spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment